Thursday, 15 October 2026European Markets

BARBARA BUI Stock Bearish Momentum With A 27% Slide In The Last 21 Sessions

Loading stream...

(vianews) - shares of barbara bui (cac 40: bui.pa) dropped by a staggering 27.84% in 21 sessions from €9.7 to €7.00 at 17:53 est on friday, after four successive sessions in a row of losses. cac 40 is jumping 0.38% to €7,397.54, after five successive sessions in a row of gains.

barbara bui's last close was €7.00, 33.33% below its 52-week high of €10.50.

about barbara bui

barbara bui sa engages in the manufacture, marketing, and sale of ready-to-wear clothing and accessories for women in france and internationally. the company offers jackets, tops and shirts, t-shirts, pants, dresses and skirts, coats, leather products, mesh, and tailored cloths; shoes; bags; and accessories, such as scarves, belts, card holder and key ring, wallets, and jewelries. it offers its products through wholesale distributors, as well as online and offline stores. the company was founded in 1983 and is based in paris, france.

earnings per share

as for profitability, barbara bui has a trailing twelve months eps of €1.61.

pe ratio

barbara bui has a trailing twelve months price to earnings ratio of 4.35. meaning, the purchaser of the share is investing €4.35 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 61.8%.

revenue growth

year-on-year quarterly revenue growth grew by 7.9%, now sitting on 10.92m for the twelve trailing months.

moving average

barbara bui's worth is way below its 50-day moving average of €9.24 and way below its 200-day moving average of €7.86.

more news about barbara bui (bui.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
BARBARA BUI Stock Bearish Momentum With A 27% Slide In The Last 21 Sessions | ViaNews EU